Noile-Immune Biotech Inc. Logo

Noile-Immune Biotech Inc.

Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.

4893 | T

Overview

Corporate Details

ISIN(s):
JP3759560000
LEI:
Country:
Japan
Address:
港区芝大門二丁目12番10号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in CAR-T cell therapy aimed at treating solid tumors, a significant challenge in oncology. Its core is the proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology, a next-generation platform designed to augment the efficacy of CAR-T cells. Noile-Immune advances its therapeutic pipeline through in-house research and strategic partnerships with academic and corporate entities, with the mission to create transformative treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:15
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 09:14
Interim Report
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 143.9 KB
2025-04-01 09:11
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-03-28 05:44
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 05:43
Governance Information
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-28 05:42
Annual Report
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 4.1 MB
2024-10-15 05:07
Report Publication Announcement
訂正確認書
Japanese 8.2 KB
2024-10-15 05:06
Interim Report
訂正半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 124.4 KB
2024-08-13 05:02
Interim Report
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 150.3 KB
2024-08-13 05:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:05
Quarterly Report
四半期報告書-第10期第1四半期(2024/01/01-2024/03/31)
Japanese 117.7 KB
2024-04-02 06:49
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-03-29 06:19
Registration Form
確認書
Japanese 8.2 KB
2024-03-29 06:18
Governance Information
内部統制報告書-第9期(2023/01/01-2023/12/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Noile-Immune Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Noile-Immune Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Noile-Immune Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan
4587

Talk to a Data Expert

Have a question? We'll get back to you promptly.